News
Article
Author(s):
The company pointed the President to existing published research and pledged to post more to its site.
Pfizer issued a response to President Trump's demands for information about the success of the COVID vaccines.
President Trump is looking for answers and Pfizer is giving them.
The pharma company issued a response to a post from the President that demands answers to questions about the success of the COVID-19 vaccines. The post, which appeared on the President’s Truth Social account on Labor Day,1 initially caused confusion as it’s unclear what the President’s goal actually is.
As the President points out in his post, the COVID vaccines were developed as part of Project Warp Speed (PWS), an initiative launched by President Trump during his first term. While members of his current administration have been critical of vaccines (especially mRNA vaccines), Trump has often cited PWS as one of his successes.
Trump wrote, “It is very important that the drug companies justify the success of their various Covid drugs. Many people think they are a miracle that saved millions of lives. Others disagree! With CDC being ripped apart over this question, I want the answer, and I want it NOW. I have been shown information from Pfizer, and others, that is extraordinary, but they never seem to show those results to the public.”
The post continues to claim that the drug companies moved on to the next project while leaving HHS Secretary Kennedy and the CDC to determine the success or failure of the medications. It’s unclear what this means, however, as the vaccination rates and number of COVID deaths have already been measured and analyzed by many experts across the industry.
Pfizer appears to be the first major COVID vaccine producer to issue a response.2 Posted directly to the company’s website, the statement begins by reaffirming the Pfizer’s commitment to being transparent about research findings regarding its COVID vaccine.
“The success of Operation Warp Speed (OWS) and U.S. development of mRNA vaccines is a profound public health achievement,” Pfizer continues. “Under President Trump's leadership, American innovation led the world, helping prevent economic collapse and saving more than 14 million lives globally. Operation Warp Speed restored consumer confidence, saved over $1 trillion in health care costs due to reductions in serious illness and avoidance of hospitalizations, and rapidly scaled up domestic production. This American leadership also delivered a new platform that may drive significant innovation in cancer research. Such an accomplishment would typically be worthy of the Nobel Peace Prize, given its significant impact.”
Pfizer then goes on to say that the President’s call for transparency is “welcomed” and that its vaccine has already been the subject of over 600 peer-reviewed publications. Data regarding the vaccine and its effectiveness has reportedly been provided to regulators at over 130 countries and RWD evidence of its impact has been generated across the world.
Pfizer then posted a link to an already existing section of its website that contains multiple published studies. The company then pledged to post more data by the end of the month.
“In the coming days, we will share new data regarding our latest vaccine strain which the FDA approved after a meticulous review by experienced medical and clinical experts,” the post continues. “We agree with President Trump about the role data and transparency play in helping to inform patients and providers about their decision to vaccinate.”
While the White House has yet to confirm any specifics about the data President Trump is requesting,3 CNN reports that White House spokesman Kush Desai said, “The only driving principle of health decision-making in this Administration is Gold Standard Science. HHS, the FDA, and the CDC will continue to take an evidence-based approach to evaluate pharmaceutical treatments and Make America Healthy Again.”
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.